ACE 2026 - September 8th
The bimonthly news publication for aviation professionals.
PAD Aviation, a premier Germany-based private aviation operator, is taking investment from TransMedics Group, a US medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure.
The proposed strategic investment is intended to support TransMedics' ongoing efforts to replicate its successful US National OCS Program (NOP), a complete, end-to-end donor organ retrieval and clinical management service that delivers donor organs on demand to U.S. transplant centres. TransMedics plans to build a dedicated organ transplantation air and ground logistics network in Europe in support of its OCS perfusion platform and clinical services, with the goal of expanding access to donor organs and increasing transplant volumes for patients in need across the EU.
“Building a dedicated transplant air logistics network in Europe is a necessary first step to supporting our European NOP strategy to bring the full benefits of our OCS technology and integrated logistics model to European patients in need of transplantation. We are already actively building our presence in Italy and our sights are set on expanding access to donor organs and increasing transplant volumes for patients across Europe over time. We look forward to working with the PAD team to advance this vision over the years ahead,” says Waleed Hassanein, president and chief executive officer of TransMedics.
PAD Aviation operates from its 24/7 hub in Paderborn, Germany, offering easy access to destinations across Europe. The company operates a fleet of nine Embraer Phenom 300 aircraft and employs more than 40 type-rated pilots. PAD Aviation holds a valid EASA AOC.
The proposed strategic investment is subject to the satisfaction of closing conditions specified in the definitive agreement between the parties as well as applicable regulatory conditions. TransMedics expects the transaction to close later in 2026 but can provide no assurance that the proposed transaction will be consummated. Financial terms are not being disclosed.
